Aerosolized Plus Intravenous Polymyxin B Versus Colistin in the Treatment of Pandrug-Resistant Klebsiella Pneumonia-mediated Ventilator-Associated Pneumonia: A Retrospective Cohort Study in Bangladesh
This work is licensed under the Creative Commons Attribution 4.0 International License.
1. Zimlichman E, Henderson D, Tamir O, Franz C, Song P, Yamin CK, et al. Health care-associated infections: a meta-analysis of costs and financial impact on the US health care system. JAMA Intern Med 2013;173(22):2039–46.ZimlichmanEHendersonDTamirOFranzCSongPYaminCKHealth care-associated infections: a meta-analysis of costs and financial impact on the US health care system.2013;173(22):2039–46.Search in Google Scholar
2. Wu D, Wu C, Zhang S, Zhong Y. Risk factors of ventilator-associated pneumonia in critically iii patients. Front Pharmacol 2019;10:482.WuDWuCZhangSZhongY.Risk factors of ventilator-associated pneumonia in critically iii patients.2019;10:482.Search in Google Scholar
3. Kalil AC, Metersky ML, Klompas M, Muscedere J, Sweeney DA, Palmer L B, et al. Management of adults with hospital-acquired and ventilator-associated pneumonia: 2016 clinical practice guidelines by the infectious diseases society of america and the american thoracic society. Clin Infect Dis 2016;63:e61–e111.KalilACMeterskyMLKlompasMMuscedereJSweeneyDAPalmer LBManagement of adults with hospital-acquired and ventilator-associated pneumonia: 2016 clinical practice guidelines by the infectious diseases society of america and the american thoracic society.2016;63:e61–e111.Search in Google Scholar
4. Martin-Loeches I, Rodriguez AH, Torres A. New guidelines for hospital-acquired pneumonia/ventilator-associated pneumonia. Curr Opin Crit Care 2018;24:347–52.Martin-LoechesIRodriguezAHTorresA.New guidelines for hospital-acquired pneumonia/ventilator-associated pneumonia.2018;24:347–52.Search in Google Scholar
5. Ding C, Zhang Y, Yang Z, Wang J, Jin A, Wang W, et al. Incidence, temporal trend and factors associated with ventilator-associated pneumonia in mainland China: a systematic review and meta-analysis. BMC Infect Dis 2017;17(1):468.DingCZhangYYangZWangJJinAWangWIncidence, temporal trend and factors associated with ventilator-associated pneumonia in mainland China: a systematic review and meta-analysis.2017;17(1):468.Search in Google Scholar
6. Karim MR, Mayedah R, Cader F A. Ventilator-associated pneumonia in Coronary Care Unit of a tertiary level hospital in Bangladesh: causative organisms and pattern of antibiotic sensitivity. Bangladesh Critical Care Journal 2019;7(2):73–6.KarimMRMayedahRCaderF A.Ventilator-associated pneumonia in Coronary Care Unit of a tertiary level hospital in Bangladesh: causative organisms and pattern of antibiotic sensitivity.2019;7(2):73–6.Search in Google Scholar
7. Pontikis K, Karaiskos I, Bastani S, Dimopoulos G, Kalogirou M, Katsiari M, et al. Outcomes of critically ill intensive care unit patients treated with fosfomycin for infections due topandrug-resistant and extensively drug-resistant carbapenemase-producing Gram-negative bacteria. Int J Antimicrob Agents 2014;43(1):52–9.PontikisKKaraiskosIBastaniSDimopoulosGKalogirouMKatsiariMOutcomes of critically ill intensive care unit patients treated with fosfomycin for infections due topandrug-resistant and extensively drug-resistant carbapenemase-producing Gram-negative bacteria.2014;43(1):52–9.Search in Google Scholar
8. Juan CH, Fang SY, Chou CH, Tsai TY, Lin YT. Clinical characteristics of patients with pneumonia caused by Klebsiella pneumoniae in Taiwan and prevalence of antimicrobial-resistant and hypervirulent strains: a retrospective study. Antimicrob Resist Infect Control 2020;9(1):4.JuanCHFangSYChouCHTsaiTYLinYT.Clinical characteristics of patients with pneumonia caused by Klebsiella pneumoniae in Taiwan and prevalence of antimicrobial-resistant and hypervirulent strains: a retrospective study.2020;9(1):4.Search in Google Scholar
9. Navon-Venezia S, Kondratyeva K, Carattoli A. Klebsiella pneumoniae: a major worldwide source and shuttle for antibiotic resistance. FEMS Microbiol Rev 2017;41:252–75.Navon-VeneziaSKondratyevaKCarattoliA.Klebsiella pneumoniae: a major worldwide source and shuttle for antibiotic resistance.2017;41:252–75.Search in Google Scholar
10. Tuon FF, Graf ME, Merlini A, Rocha JL, Stallbaum S, Arend LN, et al. Risk factors for mortality in patients with ventilator-associated pneumonia caused by carbapenem-resistant Enterobacteriaceae. Braz J Infect Dis 2017;21(1):1–6.TuonFFGrafMEMerliniARochaJLStallbaumSArendLNRisk factors for mortality in patients with ventilator-associated pneumonia caused by carbapenem-resistant Enterobacteriaceae.2017;21(1):1–6.Search in Google Scholar
11. Capone A, Giannella M, Fortini D, Giordano A, Meledandri M, Ballardini M, et al. High rate of colistin resistance among patients with carbapenem-resistant Klebsiella pneumoniae infection accounts for an excess of mortality. Clin Microbiol Infect 2013;19(1):E23–E30.CaponeAGiannellaMFortiniDGiordanoAMeledandriMBallardiniMHigh rate of colistin resistance among patients with carbapenem-resistant Klebsiella pneumoniae infection accounts for an excess of mortality.2013;19(1):E23–E30.Search in Google Scholar
12. Tran TB, Velkov T, Nation RL, Forrest A, Tsuji BT, Bergen PJ, et al. Pharmacokinetics/pharmacodynamics of colistin and polymyxin B: are we there yet? Int J Antimicrob Agents 2016;48(6):592–7.TranTBVelkovTNationRLForrestATsujiBTBergenPJPharmacokinetics/pharmacodynamics of colistin and polymyxin B: are we there yet?2016;48(6):592–7.Search in Google Scholar
13. Hasan MJ. Polymyxins nebulization over intravenous injection: pharmacokinetics and pharmacodynamics-based therapeutic evaluation. J Pharm Res Int 2019;25(4):1–10.HasanMJ.Polymyxins nebulization over intravenous injection: pharmacokinetics and pharmacodynamics-based therapeutic evaluation.2019;25(4):1–10.Search in Google Scholar
14. Hasan MJ, Rabbani R, Anam AM, Santini A, Huq SMR. The Susceptibility of MDR-K. pneumoniae to polymyxin b plus its nebulised form versus polymyxin b alone in critically ill south asian patients. J Crit Care Med (Targu Mures) 2021;7(1):28–36.HasanMJRabbaniRAnamAMSantiniAHuqSMR.The Susceptibility of MDR-K.2021;7(1):28–36.Search in Google Scholar
15. Standards of clinical and laboratory standards institute (CLSI). Performance Standards for Antimicrobial Susceptibility Testing. 30th ed. CLSI supplement M100. Wayne, PA: Clinical and Laboratory Standards Institute; 2020. https://clsi.org/media/3481/m100ed30_sample.pdf Available at. (accessed 20 April 2021)Standards of clinical and laboratory standards institute (CLSI).Performance Standards for Antimicrobial Susceptibility Testing.30th ed..Wayne, PA:Clinical and Laboratory Standards Institute;2020.https://clsi.org/media/3481/m100ed30_sample.pdf Available at. (accessed20 April 2021)Search in Google Scholar
16. EUCAST: European Committee on Antimicrobial Susceptibility Testing breakpoint tables for interpretation of MICs and zone diameters, Eleventh Version. 2021. Available at: https://www.eucast.org/fileadmin/src/media/PDFs/EUCAST_files/Breakpoint_tables/v_11.0_Breakpoint_Tables.pdf (accessed 20 April 2021)..2021. Available at:https://www.eucast.org/fileadmin/src/media/PDFs/EUCAST_files/Breakpoint_tables/v_11.0_Breakpoint_Tables.pdf (accessed20 April 2021).Search in Google Scholar
17. Fernando SM, Tran A, Cheng W, Klompas M, Kyeremanteng K, Mehta S, et al. Diagnosis of ventilator-associated pneumonia in critically ill adult patients-a systematic review and meta-analysis. Intensive Care Med 2020;46(6):1170–9.FernandoSMTranAChengWKlompasMKyeremantengKMehtaSDiagnosis of ventilator-associated pneumonia in critically ill adult patients-a systematic review and meta-analysis.2020;46(6):1170–9.Search in Google Scholar
18. Leuppi-Taegtmeyer AB, Decosterd L, Osthoff M, Mueller NJ, Buclin T, Corti N. Multicenter Population Pharmacokinetic Study of Colistimethate Sodium and Colistin Dosed as in Normal Renal Function in Patients on Continuous Renal Replacement Therapy. Antimicrob Agents Chemother 2019;63(2):e01957–18.Leuppi-TaegtmeyerABDecosterdLOsthoffMMuellerNJBuclinTCortiN.Multicenter Population Pharmacokinetic Study of Colistimethate Sodium and Colistin Dosed as in Normal Renal Function in Patients on Continuous Renal Replacement Therapy.2019;63(2):e01957–18.Search in Google Scholar
19. Lin YW, Zhou Q, Onufrak NJ, Wirth V, Chen K, Wang J, et al. Aerosolized polymyxin b for treatment of respiratory tract infections: determination of pharmacokinetic-pharmacodynamic indices for aerosolized polymyxin b against Pseudomonas aeruginosa in a mouse lung infection model. Antimicrob Agents Chemother 2017;61(8):e00211–17.LinYWZhouQOnufrakNJWirthVChenKWangJAerosolized polymyxin b for treatment of respiratory tract infections: determination of pharmacokinetic-pharmacodynamic indices for aerosolized polymyxin b against Pseudomonas aeruginosa in a mouse lung infection model.2017;61(8):e00211–17.Search in Google Scholar
20. Hasan M J, Rabbani R, Bachar S C. Therapeutic specification of the last resort polymyxins: an intelligent approach, Int J Infect 2019;6(4):e96828.Hasan MJRabbaniRBacharS C.Therapeutic specification of the last resort polymyxins: an intelligent approach,2019;6(4):e96828.Search in Google Scholar
21. Sarda C, Fazal F, Rello J. Management of ventilator-associated pneumonia (VAP) caused by resistant gram-negative bacteria: which is the best strategy to treat? Expert Rev Respir Med 2019;13(8):787–98.SardaCFazalFRelloJ.Management of ventilator-associated pneumonia (VAP) caused by resistant gram-negative bacteria: which is the best strategy to treat?2019;13(8):787–98.Search in Google Scholar
22. Yapa SWS, Li J, Patel K, Wilson JW, Dooley MJ, George J, et al. Pulmonary and systemic pharmacokinetics of inhaled and intravenous colistin methanesulfonate in cystic fibrosis patients: targeting advantage of inhalational administration. Antimicrob Agents Chemother 2014;58(5):2570–9.YapaSWSLiJPatelKWilsonJWDooleyMJGeorgeJPulmonary and systemic pharmacokinetics of inhaled and intravenous colistin methanesulfonate in cystic fibrosis patients: targeting advantage of inhalational administration.2014;58(5):2570–9.Search in Google Scholar
23. Imberti R, Cusato M, Villani P, Carnevale L, Iotti GA, Langer M, et al. Steady-state pharmacokinetics and BAL concentration of colistin in critically ill patients after IV colistin methanesulfonate administration. Chest 2010;138(6):1333–9.ImbertiRCusatoMVillaniPCarnevaleLIottiGALangerMSteady-state pharmacokinetics and BAL concentration of colistin in critically ill patients after IV colistin methanesulfonate administration.2010;138(6):1333–9.Search in Google Scholar
24. Athanassa ZE, Markantonis SL, Fousteri MZ, Myrianthefs PM, Boutzouka EG, Tsakris Aet al. Pharmacokinetics of inhaled colistimethate sodium (CMS) in mechanically ventilated critically ill patients. Intensive Care Med 2012;38(11):1779–86.AthanassaZEMarkantonisSLFousteriMZMyrianthefsPMBoutzoukaEGTsakrisAPharmacokinetics of inhaled colistimethate sodium (CMS) in mechanically ventilated critically ill patients.2012;38(11):1779–86.Search in Google Scholar
25. Lin YW, Zhou Q, Onufrak NJ, Wirth V, Chen K, Wang J, et al. Aerosolized Polymyxin B for Treatment of Respiratory Tract Infections: Determination of Pharmacokinetic-Pharmacodynamic Indices for Aerosolized Polymyxin B against Pseudomonas aeruginosa in a Mouse Lung Infection Model. Antimicrob Agents Chemother 2017;61(8):e00211–17.LinYWZhouQOnufrakNJWirthVChenKWangJAerosolized Polymyxin B for Treatment of Respiratory Tract Infections: Determination of Pharmacokinetic-Pharmacodynamic Indices for Aerosolized Polymyxin B against Pseudomonas aeruginosa in a Mouse Lung Infection Model.2017;61(8):e00211–17.Search in Google Scholar
26. Xu Q, Xu T, Zhuang Y, Liu X, Li Y, Chen Y. In Vivo Development of Polymyxin B Resistance in Klebsiella pneumoniae owing to a 42 bp Deletion in the Sequence of phoQ. Biomed Res Int. 2020;2020:5868479.XuQXuTZhuangYLiuXLiYChenY.In Vivo Development of Polymyxin B Resistance in Klebsiella pneumoniae owing to a 42 bp Deletion in the Sequence of phoQ..2020;2020:5868479.Search in Google Scholar